Skip to main content
. 2020 Aug 11;42(1):799–806. doi: 10.1080/0886022X.2020.1803085

Table 3.

Characteristics of patients newly prescribed a phosphate binder, stratified according to the presence or absence of a PPI.

  LC
 FCH
 SFOH
Without PPI (n = 9) With PPI (n = 10) p-value Without PPI (n = 7) With PPI (n = 20) p-value Without PPI (n = 7) With PPI (n = 18) p-value
Age (years) 60 ± 5 61 ± 7 0.776a 58 ± 13 62 ± 11 0.470a 61 ± 9 64 ± 9 0.535a
Male (%) 56 40 0.656d 86 85 1.000d 71 28 0.075d
Body weight (kg) 62 ± 10 54 ± 17 0.236a 65 ± 17 66 ± 16 0.846a 55 (51–70) 51 (47–66) 0.318b
Body mass index (kg/m2) 23.7 ± 3.6 21.1 ± 4.2 0.176a 23.7 ± 5.6 23.2 ± 3.9 0.786a 22.2 ± 5.3 22.1 ± 4.6 0.941a
HD vintage (months) 111 (51–362) 73 (48–133) 0.438b 62 (36–106) 97 (59–167) 0.234b 67 ± 128 224 ± 153 0.025a
Duration of HD session (hours) 4 (4–4) 4 (4–4) 0.967b 4 (4–4) 4 (4–4) 0.451b 4 (3–4) 4 (4–4) 0.044b
Kt/V 1.46 ± 0.18 1.58 ± 0.34 0.356a 1.44 (1.38–1.47) 1.41 (1.32–1.49) 0.846b 1.27 ± 0.16 1.58 ± 0.26 0.008a
nPCR (g/kg/day) 1.1 (0.9–1.3) 1.0 (0.9–1.3) 1.000b 1.1 ± 0.3 1.0 ± 0.2 0.296a 1.1 ± 0.3 1.1 ± 0.2 0.849a
ESRD etiology (%)     0.057c     0.401c     0.686c
 Glomerulonephritis 67 10   71 40   43 44  
 Diabetes 22 30   14 25   29 17  
 Hypertension 0 20   0 10   0 17  
 Polycystic kidney disease 0 0   0 20   0 6  
 Others 11 40   14 5   29 17  
Co-treatment of CKD-MBD (%)
 Calcium carbonate 67 50 0.650d 57 61 1.000d 86 50 0.179d
 Sevelamer or bixalomer 22 10 0.582d 14 25 1.000d 29 6 0.180d
 LC – –   43 60 0.662d 14 67 0.030d
 FCH or SFOH 22 50 0.350d – –   – –  
 Vitamin D analogues 89 80 1.000d 100 95 1.000d 71 78 1.000d
 Calcimimetics 56 50 1.000d 14 40 0.363d 14 56 0.090d
Prescribed amount (mg/day) 500 ± 217 700 ± 230 0.068a 500 (500–750) 750 (500–750) 0.453b 250 (250–500) 500 (250–750) 0.237b
Duration from prescription to post-examination (days) 18.2 ± 6.7 18.5 ± 5.9 0.924a 12 (12–12) 13 (12–20) 0.437b 15.3 ± 4.6 17.2 ± 4.4 0.322a
Gastrofiberscopy findings (%)     0.150c     0.123c     0.056c
 Normal 0 20   0 15   0 11  
 Reflux esophagitis 22 20   0 25   0 33  
  Gastritis 44 30   57 45   43 44  
 Gastric ulcer 0 20   0 5   0 0  
 Gastric cancer 0 10   0 5   0 0  
 Not performed 33 0   43 5   57 11  
Reasons of PPI prescription (%)
 Reflux esophagitis – 10   – 30   – 28  
 Gastric lesions – 70   – 65   – 39  
 Prevention of gastric bleeding – 40   – 25   – 39  
 Unspecified – 20   – 10   – 11  
Name of PPI prescribed (%)                  
 Omeprazole – 30   – 5   – 28  
 Lansoprazole – 10   – 35   – 22  
 Rabeprazole – 30   – 20   – 22  
 Esomeprazole – 20   – 40   – 22  
 Vonoprazan – 10   – 0   – 6  

aUnpaired t-test.

bMann–Whitney rank-sum test.

cχ2 test.

dFisher’s exact test.